SW · PPGN.SW
PolyPeptide Group AG
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Baar 6300
- Website
- polypeptide.com
Price · as of 2024-12-31
$38.15
Market cap 839.63M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $22.70 | -40.5% |
| Intrinsic Value(DCF) | $8.45 | -77.85% |
| Graham-Dodd Method(GD) | $7.40 | -80.6% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $5.20 | $16.30 | |||
| 2020 | $10.40 | $18.00 | |||
| 2021 | $78.23 | $61.90 | $24.91 | $19.20 | $45.20 |
| 2022 | $23.84 | $46.86 | $0.00 | $8.90 | $1.70 |
| 2023 | $16.83 | $45.23 | $0.00 | $3.50 | $0.00 |
| 2024 | $19.56 | $24.31 | $0.00 | $7.40 | $0.00 |
AI valuation
Our deep-learning model estimates PolyPeptide Group AG's (PPGN.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $22.70
- Current price
- $38.15
- AI upside
- -40.5%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$8.45
-77.85% upside
Graham-Dodd
$7.40
-80.6% upside
Graham Formula
—
— upside
About PolyPeptide Group AG
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
- CEO
- Juan Jose Gonzalez
- Employees
- 1.36K
- Beta
- 1.12
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($8.45 ÷ $38.15) − 1 = -77.85% (DCF, example).